Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Business Wire October 16, 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Business Wire October 13, 2023

Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

Business Wire October 13, 2023

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Business Wire October 11, 2023

Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity

Business Wire October 11, 2023

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Business Wire October 11, 2023

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

GlobeNewswire October 10, 2023

Incyte to Report Third Quarter Financial Results

Business Wire October 10, 2023

Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress

Business Wire September 29, 2023

Incyte to Present at Upcoming Investor Conferences

Business Wire August 22, 2023

Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire August 1, 2023

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Business Wire July 31, 2023

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

PR Newswire July 24, 2023

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Business Wire July 11, 2023

Incyte to Report Second Quarter Financial Results

Business Wire July 11, 2023

MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Business Wire July 5, 2023

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Business Wire May 25, 2023

Incyte to Present at Upcoming Investor Conferences

Business Wire May 23, 2023

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

Business Wire May 8, 2023

Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire May 2, 2023